Great Week for Indivior PLC (LON:INDV) Institutional Investors After Losing 23% Over the Previous Year
Indivior Transitions to US GAAP for Enhanced Market Positioning
Madison Avenue Partners Increases Stake in Indivior PLC
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $15.16
Indivior Announces Total Voting Rights and Capital Update
Indivior Announces Share Repurchase and Cancellation
Indivior Director Acquires Significant Shareholding
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $24.41
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Indivior (INDV)
Indivior CFO to Step Down From Board Following Discussions With Oaktree Capital
Indivior PLC Restructures Board to Enhance Shareholder Value
Indivior (LON:INDV) Shareholder Returns Have Been Enviable, Earning 366% in 5 Years
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $16
Indivior Management to Meet Virtually With Northland
Indivior to Engage With Investors at Healthcare Conference
Indivior Shares Sublocade Trial Findings at CSAM Conference
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior PLC Executes Strategic Share Repurchase
Indivior's Voting Rights Shift With Madison Avenue